Delaware Court Affirms Exelixis Patents in Cancer Drug Dispute with MSN Laboratories

A Delaware federal judge has upheld the validity of three patents held by Exelixis in a case involving their cancer drug, Cabometyx. This decision comes amidst opposition from MSN Laboratories Private Ltd., who argued that producing a generic version of the drug would result in patent infringement. While the court refuted the invalidity claims against these three patents, it also concluded that a fourth patent, while not invalid, was not infringed upon by MSN’s actions. For further details on this legal development, refer to the Law360 article.